Key Takeaways
- Board oversight should focus on assumptions, capabilities, investment, leadership, risk and progress—not every launch tactic.
- Ask who the real addressable patient is, who controls adoption and what could prevent access.
- Leadership should be able to name the five greatest launch risks immediately.
- Readiness must translate into measurable milestones the board can challenge before launch.
Boards do not need to manage the launch. They do need enough commercial visibility to understand whether management has identified the major risks.
The following questions can help. They pair well with a commercial readiness checklist and board commercial advisory.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
